Form 4 for DXCM Dexcom
Accepted 2024-05-16 00:00:00 ET · period of report 2024-05-15 · accession 0001093557-24-000083 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-05-16 | 2024-05-15 | DXCM | Dolan Matthew Vincent | EVP Strategy, Corp. Dev | S - Sale | $126.58 | -2,423 | 40.1K | -6% | -$306.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-05-15 | S | D | 2,423 | $126.58 | 40,075 | D | — | — | (F1) On December 15, 2023, Mr. Dolan adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Dolan. The shares set forth above were sold pursuant to the 10b5-1 Plan. (F2) Included in this number are 40,075 unvested restricted stock units, 21,711 of which were granted on March 8, 2024 and shall vest through March 8, 2027, 14,512 of which were granted on March 8, 2023 and shall vest through March 8, 2026, and 3,852 of which were granted on March 8, 2022 and shall vest through March 8, 2025 and 121 additional shares purchased pursuant to the DexCom, Inc. 2015 Employee Stock Purchase Plan. |